{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT00884520: Early Phase 1 Interventional Completed Lung Cancer
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
USAN:SODIUM TRIMETAPHOSPHATE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Sodium tripolyphosphate hexahydrate (sodium trimetaphosphate) is used in laundry detergent as a detergent "builder". It may also be used as a buffering agent. It has been shown that fluoride varnishes containing sodium trimetaphosphate reduce enamel demineralization. Sodium trimetaphosphate enhances the effect of 250 p.p.m. fluoride toothpaste against enamel demineralization in vitro. It also demonstrated significant antimicrobial activity, especially against S. mutans, and may be considered a potential alternative for new dental materials.
Status:
Investigational
Source:
NCT01682473: Phase 1 Interventional Completed Neoplasms
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
ZSTK474 is a new PI3K inhibitor with strong antitumor activity against human cancer xenografts without toxic effects in critical organs. Specifically, ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. ZSTK474 blocks VEGF-induced cell migration and the tube formation in human umbilical vein endothelial cells (HUVECs), and inhibits the expression of HIF-1α and secretion of VEGF in RXF-631L cells, exhibiting potent in vitro antiangiogenic activity. ZSTK474 demonstrated prophylactic efficacy in a rat model of rheumatoid arthritis (RA) through inhibition of T cell and FLS functions.
Status:
Investigational
Source:
NCT01200524: Phase 2 Interventional Completed Nerve Pain
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01019928: Phase 2 Interventional Completed Sensitivity in Esophagus
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03928249: Not Applicable Interventional Completed Pre Diabetes
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04452500: Phase 2 Interventional Recruiting PTSD
(2022)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
NCT00915356: Phase 2 Interventional Completed Atrial Fibrillation
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
AZD1305, an antiarrhythmic agent, blocks the hERG potassium channel, the L-type calcium, and the Sodium channel protein Nav1.5. AZD1305 participated in clinical trials for the management of atrial fibrillation and Left ventricular dysfunction. The benefit-risk profile was judged as unfavorable and the AZD1305 development programme was discontinued.
Status:
Investigational
Source:
NCT02474667: Phase 3 Interventional Unknown status Delayed Graft Function
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01200394: Phase 2 Interventional Completed Diabetic Nephropathies
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
PF-00489791 is the novel, selective and long-acting phosphodiesterase type 5 (PDE5) inhibitor. PF-00489791 was safe and generally well tolerated in overt diabetic nephropathy patient population. Most common adverse events were mild in severity and included headache and upper gastrointestinal events. PF-00489791 is the first long-acting PDE5 inhibitor to demonstrate significant reduction of albuminuria when added to standard of care therapy in subjects with type 2 diabetes mellitus and overt diabetic nephropathy. In addition, PF-00489791 causes a clinically meaningful and sustained blood pressure lowering in patients with hypertension.
